1-6 of 366 Activities
This CMEO Journal Club will equip HCPs with the latest evidence from recent clinical trials and scientific literature, enabling them to evaluate new prophylactic strategies and incorporate non-factor therapies into comprehensive, individualized treatment plans. Expert faculty will translate data into real-world insights to support improved patient outcomes and long-term disease management.
In this CMEO recorded webcast, expert faculty will present and discuss advances in non-factor therapies for hemophilia, including advancements in laboratory and monitoring practices and how to use shared decision-making (SDM) with patients to design individualized care plans that incorporate non-factor replacement therapies into treatment.
Immunoglobulin A nephropathy (IgAN) is a progressive glomerular disease and a leading cause of chronic kidney disease (CKD), with up to 40% of patients advancing to kidney failure within two decades. Despite guideline-recommended management emphasizing supportive care and RAAS inhibition, many patients continue to experience persistent proteinuria and declining renal function. Clinical practice remains inconsistent, particularly regarding the use of assessment tools and initiation of immunosuppressive therapies. While updated risk scoring models, AI-driven risk stratification tools, and biomarker-guided assessments have emerged, awareness and utilization in routine care are limited. As new therapies enter practice, clinicians require practical education to incorporate evolving evidence into patient care. To meet this need, a virtual journal club series will deliver concise, case-based learning that translates recent clinical trial findings into actionable strategies. This format is designed to foster reflection, support informed decision-making, and help nephrologists and other HCPs optimize treatment pathways for patients living with IgAN.
In this CME Outfitters recorded webcast, expert faculty will discuss the role of FcRn in the pathogenesis of gMG, evaluate the safety and efficacy of FcRn antagonists for the treatment of gMG, and provide expert guidance on how to identify patients with gMG who may be appropriate candidates for treatment with FcRn antagonists. Finally, they will model development of optimized and individualized treatment plans for patients with gMG receiving FcRn antagonists, providing learners with key skills to bring back to clinical practice.
In this CMEO Journal Club, expert faculty will present and discuss the very latest research abstracts from the American Academy of Neurology (AAN) 2025 Annual Meeting and the Associated Professional Sleep Societies (APSS) SLEEP 2025 Annual Meeting, including the latest information on psychiatric and CV/CM comorbidities for patients living with IH and narcolepsy, the impact of these comorbidities on patients’ QoL, and how to customize treatment that mitigates risk.
This activity, presented by experts in cardiology, neurology, and advanced practice care, will better equip clinicians to implement best practices in diagnosis, therapeutic strategy, and MDT collaboration to improve clinical outcomes for patients with ATTRv.
